Article Text

PDF
Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
  1. L A Jones1,2,
  2. S Goodacre1,3
  1. 1
    Northern General Hospital, Sheffield, UK
  2. 2
    School of Health and Related Research, University of Sheffield, Sheffield, UK
  3. 3
    Medical Care Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK
  1. Correspondence to Dr L A Jones, Emergency Department, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK; indiana_2000{at}doctors.org.uk

Abstract

Background: A recent meta-analysis showed that intravenous and nebulised magnesium sulphate have similar levels of evidence to support their use in the treatment of acute asthma in adults. This consisted of weak evidence of effect on respiratory function and hospital admissions, with wide confidence intervals ranging from no effect to significant positive effects. Current BTS/SIGN guidelines suggest an equivocal role for intravenous magnesium sulphate and no role for nebulised magnesium sulphate. A study was performed to assess what emergency physicians currently do in their management of acute asthma.

Method: A postal survey was undertaken of all adult emergency departments within the UK. A structured questionnaire was sent to all clinical leads in emergency medicine about their current usage of both intravenous and nebulised magnesium sulphate in the treatment of acute asthma.

Results: 180 of the 251 emergency departments in the UK responded (72%). Magnesium sulphate was used in 93%, mostly because it was expected to relieve breathlessness (70%) or reduce HDU/ITU admissions (51%). It was predominantly given to those patients with acute severe asthma (84%) and life-threatening exacerbations (87%), with most stating they would give the drug if there was no response to repeated nebulisers (68%). In comparison, nebulised magnesium sulphate was only used in two emergency departments (1%). The main reason for not administering the drug via a nebuliser was insufficient evidence (51%).

Conclusions: Intravenous magnesium sulphate is widely used for acute asthma, usually for patients with severe or life-threatening asthma who have not responded to initial treatment. Nebulised magnesium sulphate, by contrast, is hardly used at all. The use of intravenous magnesium sulphate is more extensive than current guidelines or available evidence would appear to support.

Statistics from Altmetric.com

Footnotes

  • Funding None.

  • Competing interests None.

  • Provenance and Peer review Not commissioned; not externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Primary survey
    Jonathan Wyatt